Open Access
CC BY-NC-ND 4.0 · Planta Medica International Open 2019; 6(02): e63-e69
DOI: 10.1055/a-1025-0085
Original Papers
Eigentümer und Copyright ©Georg Thieme Verlag KG 2019

Supercritical Extracts from Arctium lappa as a Potential Inhibitor for the Activation of Complement System 

Pâmela Dias Fontana
1   Laboratory of Molecular Immunopathology, Clinical Hospital, Federal University of Paraná, Curitiba, Brazil
,
Lorena Bavia
1   Laboratory of Molecular Immunopathology, Clinical Hospital, Federal University of Paraná, Curitiba, Brazil
,
Fernanda Bovo
1   Laboratory of Molecular Immunopathology, Clinical Hospital, Federal University of Paraná, Curitiba, Brazil
,
Ariádine Reder C. de Souza
2   Department of Chemical Engineering, Federal University of Paraná, Curitiba, Brazil
,
Marcos Lúcio Corazza
2   Department of Chemical Engineering, Federal University of Paraná, Curitiba, Brazil
,
Iara Jose Messias-Reason
1   Laboratory of Molecular Immunopathology, Clinical Hospital, Federal University of Paraná, Curitiba, Brazil
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 10. Juli 2019
revised 28. August 2019

accepted 02. Oktober 2019

Publikationsdatum:
25. November 2019 (online)

Preview

Abstract

Arctium lappa is a perennial species of the Asteraceae family originally from Europe and Asia. Considered a weed species in the southern region of Brazil, it is popularly used as a natural anti-inflammatory. The complement system is an important component of the innate immune response. However, its exacerbated activation can lead to harmful conditions like autoimmune and inflammatory disorders. Plants that inhibit the activation of complement can be a promising tool in the treatment of inflammatory diseases. Here, we evaluated the effect of A. lappa leaves extracts on the activation of the classical and alternative pathways of complement system. Two extracts were obtained under supercritical conditions using scCO2 with ethanol as cosolvent, at 313.15K, 15 MPa (E1) and 25 MPa (E2). Classical and alternative activation were evaluated using complement fixation test. Different concentrations of A. lappa extracts E1 and E2 showed an inhibitory effect on both complement pathways, and heparin was used as control. The IC50 of E1, E2, and heparin were 28.26, 20.12 and 92.54 µg/mL for classical and 26.12, 27.70, 27.78 µg/mL for the alternative pathway. Results demonstrate that A. lappa is a promising complementary treatment for diseases associated with complement activation.